After two years of declining funding activity, biotech venture capital offered signs of a rebound in 2024. However, investor patterns have changed, with VCs favoring high-profile companies.

Antibody-Drug Conjugates (ADC)-focused biotech companies have surged back into the spotlight in 2024, attracting significant venture capital (VC) funding values and volumes.

From the perennial favourites like oncology to the booming fields of ADC and GLP-1, our latest report explores Big Pharma’s favourite drug modalities and therapeutic areas for M&A.

With revenue challenges lying ahead and plenty of cash available, Pharma top 10 is expected to increasingly turn towards M&A to secure growth in the future.

Based on our survey with 50+ prominent Venture Capitalists, we have identified 8 criteria that shape how biopharma-focused VCs evaluate potential Biotech funding in 2024.

Pharma is betting big on circular RNA to be the next generation of therapies. Here is, in a nutshell, why you should keep an eye on this exciting technology.

Discover what impact organ-on-a-chip could have on drug development and how Pharma stakeholders are investing to realise its true potential.